Related Symbol
avatar
@kewur 1 month ago

BioNTech revenue down 60%, hit with recent clinical trial setbacks

BioNTech revenue down 60%, hit with recent clinical trial setbacks

BioNTech's Q2 revenue dropped 60% to 105.6 million euros as COVID vaccine sales decline. They also posted a net loss of 3.24 euros per share. On the clinical side, they halted a Phase 2 colorectal cancer trial in August, and their BNT113 candidate just missed a primary endpoint in a head and neck cancer trial. Stock dropped 5% on the latest news. They still have a deep oncology pipeline, but it is looking like a risky play given the $23B market cap.
post thumbnail
no comments yet

There are no comments here, be the first to comment